Business
MetaStat Announces Presentation of Two MetaSite Breast™ Studies at the 2016 San Antonio Breast Cancer Symposium
MetaStat Announces Presentation of Two MetaSite Breast™ Studies at the 2016 San Antonio Breast Cancer Symposium.
About this update from Metastat Inc
[{"type":"text","content":"\n \n MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today \n announced the company will present clinical data and results from two \n studies at the San Antonio Breast Cancer Symposium (SABCS), taking place \n December 6-10, 2016 at the Henry B. Gonzalez Convention Center in San \n Antonio, TX.\n \n \n “We are pleased to have two of our studies involving MetaSite Breast™ \n accepted for presentation at this year’s San Antonio Breast Cancer \n Symposium, including an oral presentation by Dr. Joseph Sparano, \n principal investigator for the ECOG 2197 study,” stated Douglas A. \n Hamilton, CEO and President of MetaStat, Inc.\n \n \n Presentations of MetaSite Breast™ studies in patients with Early \n Stage Breast Cancer (ESBC) include:\n \n \n \n Nested case-control study (n=481, 259 case-controlled pairs) of \n MetaSite Breast™ within a cohort of 3,760 patients diagnosed \n with ESBC from the Kaiser Permanente Northwest Health Care system;\n \n \n Prospectively designed retrospective study (n=600) in an independent \n cohort (E2197; NCT00003519) of ESBC patients treated with surgery, 4 \n cycles of adjuvant chemotherapy (AC or AT) and endocrine therapy.\n \n \n \n Thursday, December 8, 2016\n \n \n Session Number: Poster Session 2, P2-05-06Session Title: \n Prognostic and Predictive Factors: Prognostic Factors – Clinical Testing \n and Validation.Abstract Title: Analytical and clinical \n validation of a fully automated tissue-based quantitative assay MetaSite Breast™ \n to detect the likelihood of distant metastasis in hormone receptor \n (HR)-positive, HER2-negative early stage breast cancer (ESBC).\n \n \n Authors: Michael J. Donovan, MD, PhD, Joan G. Jones, MD, David R. \n Entenberg, MSc, John S. Condeelis, PhD, Timothy M. D'Alfonso, MD, Mark \n Gustavson, PhD, Annette Molinaro, MA, PhD, Maja H. Oktay, MD, PhD, \n Xiaonan Xue, PhD, Joseph A. Sparano, MD, Michael A. Peterson, BSc, Olga \n Podznyakova, MD, PhD, Thomas E. Rohan, MBBS, PhD, Anthony P. Shuber, \n MSc, Frank B. Gertler, PhD, Amy Ly, MD, Michelle E. Divelbiss, MSc, \n Douglas A. Hamilton, BSc, MBA.Location: Hall 1Session \n Time: 7:30 a.m. - 9:00 a.m.\n \n \n Program Number: S4-04Oral Presentation in General \n Session 4: Tumor microenvironment of metastasis (TMEM) score is \n associated with early distan...